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Background: Excessive fluid retention is a serious complication after the maze
procedure that cannot be totally explained by changes in levels of atrial natriuretic
peptide. We therefore measured circulating levels of arginine vasopressin and
aldosterone in patients undergoing the maze procedure to study their possible role
in this postoperative complication.
Methods: Serial arginine vasopressin and aldosterone levels were monitored for 72
hours in 11 patients after coronary artery bypass grafting and in 13 patients after the
maze procedure. Hemodynamic data, urine output, fluid balance, and complications
were recorded prospectively during the same period of time.
Results: Plasma levels of arginine vasopressin and aldosterone were significantly
higher in patients after the maze procedure when compared with patients after
coronary artery bypass grafting.
Conclusions: This study documents that the maze procedure results in increased
plasma arginine vasopressin and aldosterone levels and indicates that they, rather
than atrial natriuretic peptide alone, participate in the excessive postoperative fluid
retention that follows the maze procedure. We believe that these hormone elevations
are most likely secondary to a temporary lack of response of the atrial baroreceptors.
These results may explain the effectiveness of spironolactone therapy after the maze
procedure.
The maze procedure has been demonstrated to be a safe and effectivesurgical therapy for medically refractory atrial fibrillation.1-3 One ofthe earliest recognized postoperative complications of the mazeprocedure is excessive fluid retention, with a reported incidence of12% to 36%.4,5 In its most severe form, fluid retention may result inpulmonary edema and symptomatic pleural effusion in the immedi-
ate postoperative period.
The cause of this postoperative abnormal fluid imbalance remains uncertain.
Several authors have suggested that a significant decrease in the secretion of atrial
natriuretic peptide (ANP) postoperatively may play a role in the excess fluid
retention. This hypothesis suggests that the decreased ANP levels after the maze
procedure result from the multiple atriotomy incisions and excision of both atrial
appendages rather than from the conversion of atrial fibrillation to normal sinus
rhythm.6-8 However, a significant reduction in ANP levels has also been observed
in patients after external cardioversion for chronic atrial fibrillation, which is
generally not associated with fluid retention.9 Taken together, these findings indicate
that the ANP level is not the only determinant of postoperative fluid retention seen
after the maze procedure.
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Arginine vasopressin (AVP) is released into the systemic
circulation in response to an increased plasma osmolality or
as a reflex response to decreases in blood volume- or blood
pressure-sensed baroreceptors in the atria and pulmonary
arteries.10-18 Many of the cardiovascular and renal effects of
AVP, and its stimulus for secretion, are antagonized by
ANP.11 At the level of the hypothalamo-neurohypophyseal
axis, high concentrations of ANP can inhibit AVP secretion
and adrenocorticotropic hormone release. ANP also inhibits
steroidogenesis, especially mineralocorticoid synthesis, in
the adrenal cortex. The endocrine effects of ANP therefore
complement its cardiovascular and renal effects by antago-
nizing the sodium and water retention caused by aldosterone
and AVP, respectively.12
We propose that the temporary loss of atrial stretch
receptors and possibly the decreased level of ANP after the
maze procedure result in a relative increase in AVP and
aldosterone levels. Elevated serum AVP and aldosterone, in
addition to ANP deficiency, thus participate in causing the
immediate postoperative fluid retention observed in patients
undergoing the maze procedure.
Methods
This study (1) examines serial changes in AVP levels after the
maze procedure and compares them with those after non-maze
heart surgery and (2) determines whether serum aldosterone levels
correlate with AVP changes in the same set of patients.
Patients
After the study was approved by the Georgetown University
Investigative Review Board and informed consent was obtained,
24 patients were enrolled. The subjects were divided into 2 groups:
group I, patients tested after the maze procedure (n  13), and
group II, patients tested after coronary artery bypass grafting
(CABG) (n  11). All patients underwent operation for the first
time and were admitted for surgery electively. Patients with renal
failure (serum creatinine  1.5 mg/dL) and patients receiving
preoperative treatment with diuretics or angiotensin-converting
enzyme inhibitors were excluded from the study.
Blood Samples
Blood samples were taken at 5 different time points from patients
in both groups. A baseline sample was taken in the operating room
before any anesthesia. Four samples were then taken postopera-
tively beginning at 6 hours and then at 24, 48, and 72 hours
postoperatively.
All samples were drawn into 10-mL heparinized tubes and
centrifuged immediately for 10 minutes at 4°C. The plasma was
separated and stored at 70°C until the assay for AVP, aldosterone,
and ANP levels was performed. Each blood sample was coded and
numbered so the laboratory work could be performed without know-
ing the patient’s name, type of disease, or surgical procedure.
AVP Radioimmunoassay
The plasma samples were thawed and extracted using the acetone-
ether method. Briefly, 1 mL of acetone (Fisher Chemicals, Fair
Lawn, NJ) was added to 0.5 mL of plasma and centrifuged for 20
minutes at 2600 rpm. The supernatant was removed, and 1 mL of
anhydrous ethyl ether (Merck KGaA, Darmstadt, Germany) was
added. This was allowed to settle for 30 minutes. The upper ether
phase was discarded. The remaining sample was dried with a
vacuum centrifuge and then reconstituted in 250 L of assay
buffer (0.01 mol/L K2HPO4, 1.5 mol/L NaCl, and 0.25% bovine
serum albumin, pH 7.4). The radioimmunoassay (RIA) was per-
formed by incubating 100 L of plasma extract or a known
amount of AVP standards (0.01-50 pg per tube, Peninsula Labo-
ratories, Belmont, Calif) with 100 L of anti-AVP antibody and
200 L of assay buffer for 24 hours at 0°C to 4°C. Then, 100 L
of 125I-AVP tracer (3200 cpm, NEN Life Science Products,
Boston, Mass) was added and continuously incubated for 3 to 4
days at 0°C to 4°C. Incubation was stopped by the addition of 50
L of 0.03% gamma globulin (Amersham Life Science, Arlington,
Ill) and 1 mL of 25% PEG 8000 (Fisher). Free ligand was de-
canted. The residue was counted for 1 minute using a Gamma
Counter (Titertek Instruments, Huntsville, Ala). The standard
curve and plasma AVP concentration were calculated with RIA
software AGC 2 (Titertek Instruments).
Aldosterone Radioimmunoassay
Plasma aldosterone levels were measured using the Coat-A-Count
aldosterone RIA kit from the Diagnostic Products Corporation
(Los Angeles, Calif). Briefly, 200 L of plasma and 1.0 mL
125I-aldosterone were added to polypropylene tubes coated with an
aldosterone-specific antibody. The mixture was incubated at room
temperature for 18 hours. The tubes were decanted thoroughly.
The residue was counted for 1 minute using a Gamma Counter.
The standard curve and plasma aldosterone concentrations were
calculated with RIA software AGC 2.
Atrial Natriuretic Peptide Radioimmunoassay
Plasma ANP levels were measured using the ANP RIA kit from
American Laboratory Products (Windham, NH). The plasma sam-
ples were thawed and purified using a SepPak C18 cartridge
(Waters, Milford, Mass). The cartridges were pretreated with 5 mL
of 4% acetic acid in 86% ethanol followed by 5 mL of methanol
and 5 mL of distilled water; 0.5 mL of plasma was acidified with
1.5 mL of 4% acetic acid and applied to the cartridge. The
cartridge was rinsed with 3 mL of distilled water, and then ANP
was eluted with 3 mL of acetic acid in 86% ethanol. The samples
were evaporated under a light stream of nitrogen gas and then
reconstituted in 250 L of assay buffer (0.2 mol/L borate and 0.2%
bovine serum albumin, pH 8.4). The RIA was performed by
incubating 100 L of plasma extract or known amount of stan-
dards (0.78-100 pg ANP) with 200 L anti-ANP antibody and
125I-ANP tracer overnight at 0°C to 4°C. Free ligand was decanted
thoroughly. The residue was counted for 1 minute using a Gamma
Counter. The standard curve and plasma ANP concentration were
calculated with RIA software AGC 2.
Parameters Checked
The following parameters were assessed for potential interactions
with plasma AVP and aldosterone levels: age, gender, left ven-
tricular function, blood pressure (systolic, diastolic, and mean, as
well as the changes in these parameters between the different time
Cardiopulmonary Support and Physiology Ad et al
1096 The Journal of Thoracic and Cardiovascular Surgery ● October 2003
CSP
points), cardiac index, central venous pressure, blood osmolality,
potassium level, cardiopulmonary bypass time, crossclamp time,
and plasma ANP levels.
Fluid Retention
Fluid retention was defined and classified as mild, moderate, or
severe according to different parameters, including weight, degree
of pulmonary congestion, pleural effusion, and peripheral edema.
Mild fluid retention included signs of mild pulmonary congestion
on physical examination or chest x-ray film, small pleural effusion,
the need for O2 supplement by face mask, 5% weight gain on
postoperative day 5, and mild peripheral edema. Moderate fluid
retention included clear signs of pulmonary congestion on physical
examination or chest x-ray film, moderate size of pleural effusion
requiring evacuation, the need for O2 supplement more than 12
hours per day, weight gain of 5% to 10% on postoperative day 5,
and moderate degree of peripheral edema. Severe fluid retention,
although rare, included pulmonary edema requiring reintubation,
large pleural effusion requiring evacuation, weight gain of more
than 10% on postoperative day 5, and severe degree of peripheral
edema.
Statistical Analysis
Blood samples taken over time were analyzed by 2-way analysis of
variance corrected for repeated measures. Individual means were
compared using Student-Newman-Keuls multiple comparison
tests. A 2-tailed Spearman’s rho coefficient was calculated to
assess the correlation between AVP and aldosterone levels to the
different parameters mentioned in the previous section. Subgroups
analysis was performed using an unpaired t test. The null hypoth-
esis was rejected with a P value less than .05. Data are expressed
as mean  SEM.
Results
The demographics and other parameters (described in Meth-
ods) were compared, and no significant differences were
found between the 2 groups. Analysis of serial changes in
systemic AVP and aldosterone levels after the maze proce-
dure and CABG revealed significant increases in serum
hormone levels in both groups postoperatively (Table 1).
The blood level of both hormones increased significantly in
the postoperative period, peaking within 6 to 24 hours, and
then returned to baseline within 3 days after surgery. The
increased levels of AVP and aldosterone were found to be
significantly higher in patients after the maze procedure
compared with patients after CABG (Figures 1 and 2).
Statistical analysis of the plasma AVP levels (Table 1) of
the 2 groups before and after surgery revealed significant
effects of both time (P  .001) and the maze procedure (P
 .002). Post hoc analysis using the Student-Newman-
Keuls multiple comparison test revealed a significant dif-
ference between the means for the first blood sample post-
operatively (P  .001). Analysis of the aldosterone levels
also revealed a significant effect of time (P  .001) and the
maze procedure (P  .05). Post hoc analysis using the
Student-Newman-Keuls multiple comparison test revealed
significant differences between the means for the first blood
sample postoperatively and for the first, second, and fifth
samples postoperatively (P  .001, P  .035, P  .01,
respectively).
In an attempt to identify possible predictors for the
observed differences in AVP and aldosterone levels at spe-
cific time points, we used backward stepwise regression
analysis for the different parameters that were checked (see
Methods). For plasma AVP levels, the only significant pre-
dictor for the observed difference in the samples taken 6
hours postoperatively was the maze procedure (P  .046).
Parameters that were significant predictors for the elevated
aldosterone levels 6 and 24 hours postoperatively were the
maze procedure (P  .046 and P  .039, respectively) and
cardiopulmonary bypass time (P  .041 and P  .043,
respectively). However, in this study we did not find that
cardiopulmonary bypass time was significantly longer in the
maze procedure group when compared with the CABG
group (163.1  37.1 minutes and 133  58 minutes [mean
 SD], respectively, P  .155). Aldosterone levels were
significantly higher in patients after the maze procedure at
48 hours after surgery as well; however, this is likely related
to the fact that all patients in the maze procedure group were
treated with spironolactone (75 mg/day) starting 12 hours
after the procedure. Spironolactone binds to the mineralo-
corticoid receptor in the kidney, which is intracellular. The
spironolactone cross-reacts with the aldosterone assay in
TABLE 1. Plasma AVP, aldosterone, and ANP levels after surgery
Sample timing
RAP (mm Hg)
CABG (n  11)
RAP (mm Hg)
maze (n  13)
AVP CABG
(pg/mL)
(n  11)
AVP maze
(pg/mL)
(n  13)
Aldosterone
CABG (pg/mL)
(n  11)
Aldosterone
maze (pg/mL)
(n  13)
ANP CABG
(pg/mL)
(n  9)
ANP maze
(pg/mL)
(n  10)
Preoperative 6.3 3.4 5.7 0.6 0.7 0.15 1 0.2 37 16 57 23 25.6 19.7 27.3 30.1
6 h 8.4 2.4 9.1 2.1 9.8 5.5 20.4 6.5 119 49 318 92 18.3 16.1 17 17.4
24 h 9.8 3.1 10.3 2.6 2.1 0.65 4.3 1.3 75 30.5 119 52.5 15.2 14.3 17.4 12.7
48 h 8.5 1.2 8.1 1.9 1 0.3 3.3 1.45 61 26 175 73.5 22.1 11.6 29.4 23.05
72 h — — 1.1 0.3 1.5 0.65 112 55 288 183 21.7 24.2 30.2 26.4
AVP, Arginine vasopressin; ANP, atrial natriuretic peptide; CABG, coronary artery bypass grafting; RAP, right atrial pressure. Data are presented as means
 SEM.
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use for this study. The cross-reactivity of spironolactone in
this assay is 0.06%. It is clear that the late increase in
aldosterone level is directly related to its pharmacologic
effect. However, the higher early levels of the hormone are
not related to spironolactone use. We were obligated to use
spironolactone in patients after the maze procedure because
it has been proven that patients who were not treated with
the drug after the procedure were exposed to a relatively
higher incidence of fluid retention.
We also performed a subgroup analysis (Table 2) com-
paring a subgroup of 4 patients who demonstrated a mild
degree of fluid retention after the maze procedure (subgroup
II) with the rest of the patients after the maze procedure who
did not have clinically apparent fluid retention (subgroup I).
Interestingly, the AVP levels for the patients in subgroup II
were significantly higher when compared with the patients
in subgroup I after the maze procedure at 24, 48, and 72
hours postoperatively. The same result was demonstrated
for aldosterone in the samples that were drawn 72 hours
postoperatively, when all patients were treated with spi-
ronolactone.
In this study, no significant difference was found in ANP
levels between the 2 groups (Table 1). Furthermore, sub-
group analysis for patients with fluid retention revealed no
lower level of plasma ANP in the postoperative period.
Discussion
The maze procedure is the most effective surgical approach
for the treatment of atrial fibrillation, resulting in a high
success rate in abolishing this arrhythmia.1-5 In general,
patients require relatively high amounts of diuretics to
maintain urine output after the maze procedure. This phe-
nomenon is clearly not related to postoperative renal insuf-
ficiency or low cardiac output and can lead to clinically
significant fluid retention in as many as 12% to 36% of
patients.4,5
In animal models, right atrial or bilateral atrial appen-
dectomy reduces the release of ANP and blunts the renal
excretion of sodium and water after a large acute volume
load.13-18 Because the classic maze procedure involves mul-
tiple dissections in the left and right atrial tissue, as well as
amputation of both right and left atrial appendages, previous
clinical studies attributed the fluid retention phenomenon to
the abrupt decrease in ANP levels documented after the
maze procedure.6,7 Amano and colleagues19 demonstrated
that in patients who underwent heart surgery, regardless of
whether right atrial appendectomy was performed, plasma
levels of ANP failed to increase in response to sodium
loading, whereas ANP levels increased preoperatively in
both groups after sodium loading. The same study showed
that plasma AVP levels were significantly increased by
sodium loading both before and after operation in both
groups.
The maze procedure involves a large amount of dissec-
tion, including incisions and cryosurgery to the right and left
atria. As a result, transient right and left atrial dysfunction
have been documented.20,21 Cardiopulmonary receptors lo-
cated mainly at the caval–atrial junction, not arterial barore-
ceptors, are primarily responsible for activation of region
associated with regulation of arginine-vasopressin secre-
tion.22,23 The lesions induced by the procedure can lead to
transient lost of autonomic innervation and in some cases
may cause ablation of stretch receptors (cardiopulmonary
receptors) in the atria, resulting in a loss of tonic inhibition
of AVP release.20
Although the abrupt reduction in ANP levels after the
maze procedure may be sufficient to explain some degree of
fluid retention, we believed that because of the nature of the
operation involving such an extensive dissection within and
around the atria tissue, one would expect changes in AVP
and aldosterone levels that may lead to additional stimuli for
fluid retention and may reflect on a strong stimulus to retain
fluids. Indeed, our study demonstrated higher levels of both
AVP and aldosterone in patients after the maze procedure
Figure 1. Perioperative arginine-vasopressin level. AVP, Argin-
ine-vasopressin; CABG, coronary artery bypass grafting surgery.
Figure 2. Perioperative aldosterone level. CABG, Coronary artery
bypass grafting surgery.
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when compared with a matched group of patients who
underwent CABG. Significantly higher levels of these hor-
mones were found predominantly earlier in the postopera-
tive course, correlating with the clinical occurrence of the
postoperative fluid retention in patients after the maze pro-
cedure. We find the subgroup analysis very important, al-
though it was limited by the small number of patients with
clinically apparent fluid retention, because the hormone
levels were higher at various stages of the postoperative
course in the patients who demonstrated clinical fluid reten-
tion. The current study provides new insights that allow a
better understanding of the unique phenomenon of fluid
retention after the maze procedure. It will be of interest to
evaluate the effect of the new cryosurgical maze procedure
on the hormonal secretion profile. This new approach pre-
serves the basic principles of the maze III atrial incisions;
however, it is performed using linear cryoprobes as the
means to create linear lesions. This approach seems to be
less traumatic to the atrial tissue, as can be judged by the
much better biatrial contraction early in the postoperative
course. Whether this will result in lesser effects on AVP and
aldosterone secretion with subsequent reduced degrees of
fluid retention and related complications remains to be seen.
In summary, this study documents that the maze proce-
dure results in increased plasma AVP and aldosterone levels
and indicates that they, rather than ANP alone, also partic-
ipate in the tendency for excessive postoperative fluid re-
tention that follows the maze procedure. We believe that
these hormone elevations are most likely secondary to a
temporary lack of response of the atrial baroreceptors and
reflect the presence of a strong stimulus to retain fluids after
the maze procedure. Studies are now required to dissect the
molecular events and changes in gene expression that lead
to the increased susceptibility for fluid retention. These may
also enhance the identification of perioperative treatments
that will reduce the risk for fluid retention and patients at
risk for it.
Limitations of the Study
The data obtained for this study are based on a small group
of patients. A major design problem of this study is that at
12 hours after the surgical procedure, spironolactone was
given only to the patients after the maze procedure. We are
aware that such a drug may have an impact on the results
regarding aldosterone levels recorded after 48 hours; how-
ever, because spironolactone is an important drug in reduc-
ing the fluid retention phenomenon, we were obligated to
treat patients after the maze procedure with the drug.
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